

Janssen-Cilag International, NV

Turnhoutseweg 30
2340 Beerse Belgium

JCI-Office@its.jnj.com



Memorandum

To: 68284528MMY2001 File

cc: GRAIL

From: Ivana Stracenski

Date: 12 October 2022

Re: EudraCT number 2018-000121-32

Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

EU Clinical Trial Register

Following a very successful enrollment of patients in the United States, Janssen-Cilag International, NV, considers enrollment to be complete and does not intend to recruit more patients to this study.

Janssen confirms that no patients were enrolled in this study in EU/EEA, for this reason, no results have been published to the EudraCT system.

A handwritten signature in black ink, appearing to read 'Ivana Stracenski', is positioned below the text.

Ivana Stracenski

Associate Director, EMEA Regulatory Liaison
Oncology Therapeutic Area
Janssen Research and Development

Janssen Pharmaceutical Companies of Johnson & Johnson
50 – 100 Holmers Farm Way
High Wycombe, Buckinghamshire
HP12 4DP

Tel: +44 1494 65 8620 | **Mob:** +44 7786 51 1867 | **Email:** IStracen@its.jnj.com